In 1125 men with metastatic hormone-sensitive prostate cancer, enzalutamide vs a nonsteroidal antiandrogen with testosterone suppression improved overall survival at median 8.1-year follow-up (8-year OS 50% vs 40%; HR 0.73), with more grade 3–5 falls.
RCTn = 1,125
Zhang et al. Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)